2022
DOI: 10.1016/j.cbpa.2022.102205
|View full text |Cite
|
Sign up to set email alerts
|

Mechanism and inhibition of BRAF kinase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 46 publications
0
7
0
Order By: Relevance
“…However, when we tested the B-Raf inhibitor SB590885, the resulting phenotype did not classify as “AA” either during the startle or post-startle period. Interestingly, B-Raf is also known to interact with 14-3-3, which functions to maintain its kinase domain in an inactive state 72 . The expectation therefore would be that activation of B-Raf upon disruption of 14-3-3 binding may allow it to contribute to an anxiolytic-like state, as observed with the 14-3-3 client binding inhibitor R18.…”
Section: Discussionmentioning
confidence: 99%
“…However, when we tested the B-Raf inhibitor SB590885, the resulting phenotype did not classify as “AA” either during the startle or post-startle period. Interestingly, B-Raf is also known to interact with 14-3-3, which functions to maintain its kinase domain in an inactive state 72 . The expectation therefore would be that activation of B-Raf upon disruption of 14-3-3 binding may allow it to contribute to an anxiolytic-like state, as observed with the 14-3-3 client binding inhibitor R18.…”
Section: Discussionmentioning
confidence: 99%
“…However, when we tested the B-Raf inhibitor SB590885, the resulting phenotype did not classify as "AA" either during the startle or post-startle period. Interestingly, B-Raf is also known to interact with 14-3-3, which functions to maintain its kinase domain in an inactive state 72 .…”
Section: Discussionmentioning
confidence: 99%
“…However, when we tested the B-Raf inhibitor SB590885, the resulting phenotype did not classify as “AA” either during the startle or post-startle period. Interestingly, B-Raf is also known to interact with 14–3-3, which functions to maintain its kinase domain in an inactive state 78 . The expectation therefore would be that activation of B-Raf upon disruption of 14–3-3 binding may allow it to contribute to an AA-like state, as observed with the 14–3-3 client binding inhibitor R18.…”
Section: Discussionmentioning
confidence: 99%